Author: Jones, Harrison G.; Battles, Michael B.; Lin, Chun-Chi; Bianchi, Siro; Corti, Davide; McLellan, Jason S.
Title: Alternative conformations of a major antigenic site on RSV F Document date: 2019_7_15
ID: 1r20hl2b_3
Snippet: Respiratory syncytial virus (RSV) is a ubiquitous pneumovirus which infects nearly all children in the U.S. by the age of two, with repeated infections occurring throughout life [1] . RSV is a common cause of acute lower respiratory tract infections in young children and the elderly, and in 2015 resulted in an estimated 94,000-149,000 deaths globally in children under the age of five [2] . Although few deaths of children in the United States are .....
Document: Respiratory syncytial virus (RSV) is a ubiquitous pneumovirus which infects nearly all children in the U.S. by the age of two, with repeated infections occurring throughout life [1] . RSV is a common cause of acute lower respiratory tract infections in young children and the elderly, and in 2015 resulted in an estimated 94,000-149,000 deaths globally in children under the age of five [2] . Although few deaths of children in the United States are attributed to RSV [2, 3] , severe infections requiring hospitalization are frequent and lead to estimated direct health care costs of $750 million dollars annually [4] . Currently, there is no vaccine for RSV and the only FDA-approved therapy is passive prophylaxis with the monoclonal antibody palivizumab (Synagis) [5] . However, the high cost and modest efficacy of palivizumab restricts its usage to high-risk infants [6] , making the development of improved interventions a global health priority.
Search related documents:
Co phrase search for related documents- antibody palivizumab and high cost: 1, 2, 3
- antibody palivizumab and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- antibody palivizumab and respiratory syncytial virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- antibody palivizumab and respiratory tract: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- antibody palivizumab and respiratory tract infection: 1, 2, 3, 4, 5, 6, 7
- antibody palivizumab and RSV respiratory syncytial virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- antibody palivizumab and severe infection: 1, 2, 3, 4, 5
- antibody palivizumab and Synagis antibody palivizumab: 1
- antibody palivizumab and syncytial virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- common cause and global health priority: 1
- common cause and globally death: 1, 2, 3
- common cause and health care: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45
- common cause and health priority: 1, 2, 3
- common cause and high cost: 1, 2, 3
- common cause and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55
- common cause and hospitalization require: 1, 2, 3, 4
- common cause and hospitalization require severe infection: 1
- common cause and improve intervention: 1
- common cause and life occur: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date